Magnus Nylén
Directeur/Membre du Conseil chez SELECTIMMUNE PHARMA AB (PUBL)
Profil
Magnus Nylén is currently a Director at Hamlet BioPharma AB, a Director at SelectImmune Pharma AB since 2022, and the Owner of Partner Fondkommission AB since 2013.
He completed his undergraduate degree at Boston University.
Postes actifs de Magnus Nylén
| Sociétés | Poste | Début |
|---|---|---|
| SELECTIMMUNE PHARMA AB (PUBL) | Directeur/Membre du Conseil | 23/11/2022 |
| HAMLET PHARMA AB (PUBL) | Directeur/Membre du Conseil | - |
Partner Fondkommission AB
 Partner Fondkommission AB Investment ManagersFinance Partner Fondkommission AB provides financial advisory services. It offers mergers and acquisitions, brokerage, and issuer services. The company was founded in 2007 and is headquartered in Gothenburg, Sweden. | Corporate Officer/Principal | 01/01/2013 |
Formation de Magnus Nylén
| Boston University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SELECTIMMUNE PHARMA AB (PUBL) | Health Technology |
| HAMLET PHARMA AB (PUBL) | Health Technology |
| Entreprise privées | 1 |
|---|---|
Partner Fondkommission AB
Partner Fondkommission AB Investment ManagersFinance Partner Fondkommission AB provides financial advisory services. It offers mergers and acquisitions, brokerage, and issuer services. The company was founded in 2007 and is headquartered in Gothenburg, Sweden. | Finance |
